Pfizer has started construction on a new consumer products production facility in Suzhou, China, which will involve an investment of around $95m.

The new facility is being developed to increase production capacity to meet the growing demand for its healthcare brands in China and the Asia-Pacific region.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pfizer Consumer Healthcare Asia-Pacific and Europe, Middle East and Africa regional president Andy Schmeltz said: "Asia-Pacific is a large and rapidly growing region for Pfizer Consumer Healthcare and our new plant in Suzhou will give us the production capacity we need to meet increasing demand for our brands, particularly in China."

"Our new plant in Suzhou will give us the production capacity we need to meet increasing demand for our brands, particularly in China."

The new facility will be mainly used for the production of Caltrate dietary supplements and Centrum multivitamins and will also support production of additional products in the future.

In addition, the company intends to house a research and development facility on the new site to support innovation in the region.

Pfizer Consumer Healthcare North Asia regional general manager Keith Choy said: "We are pleased to build on the strong foundation we have in Suzhou, where we have produced consumer healthcare and prescription products for more than 20 years."

Having began production in 1994, Pfizer Suzhou facility produces Centrum multivitamins, Caltrate dietary supplements, Robitussin cough and cold products, antibiotics, as well as other prescription and over-the-counter products.

Products produced in the facility will be distributed to multiple countries in the Asia Pacific region, including China.